Amit Goyal, G Bruce Mann, Lesley Fallowfield, Lelia Duley, Malcolm Reed, David Dodwell, Robert E Coleman, Apostolos Fakis, Robert Newcombe, Valerie Jenkins, Diane Whitham, Margaret Childs, David Whynes, Vaughan Keeley, Ian Ellis, Patricia Fairbrother, Shabina Sadiq, Kathryn Monson, Alan Montgomery, Wei Tan, Luke Vale, Tara Homer, Heath Badger, Rachel Helen Haines, Mickey Lewis, Daniel Megias, Zohal Nabi, Preetinder Singh, Andrei Caraman, Elizabeth Miles
INTRODUCTION: ACOSOG-Z0011(Z11) trial showed that axillary node clearance (ANC) may be omitted in women with ≤2 positive nodes undergoing breast conserving surgery (BCS) and whole breast radiotherapy (RT). A confirmatory study is needed to clarify the role of axillary treatment in women with ≤2 macrometastases undergoing BCS and groups that were not included in Z11 for example, mastectomy and those with microscopic extranodal invasion. The primary objective of POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy (POSNOC) is to evaluate whether for women with breast cancer and 1 or 2 macrometastases, adjuvant therapy alone is non-inferior to adjuvant therapy plus axillary treatment, in terms of 5-year axillary recurrence...
December 2, 2021: BMJ Open